Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach-Reference-Cited by-同舟云学术

Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach

Published:2021-05-08 Issue:7 Volume:32 Page:675-680
ISSN:0957-5243
Container-title:Cancer Causes & Control
language:en
Short-container-title:Cancer Causes Control

Author:

Hall Mary E.^ORCID,Bhindi Bimal,Luckenbaugh Amy N.,Laviana Aaron A.,Moses Kelvin A.,Satkunasivam Raj,Rini Brian,Klaassen Zachary,Wallis Christopher J. D.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10552-021-01435-z.pdf

Reference15 articles.

1. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171(3):1071–1076. https://doi.org/10.1097/01.ju.0000110610.61545.ae

2. Bhindi B et al (2019) Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 75(1):111–128. https://doi.org/10.1016/j.eururo.2018.09.016

3. Larcher A et al (2019) Individualised indications for cytoreductive nephrectomy: which criteria define the optimal candidates? Eur Urol Oncol 2(4):365–378. https://doi.org/10.1016/j.euo.2019.04.007

4. Mejean A et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379(5):417–427. https://doi.org/10.1056/NEJMoa1803675

5. Mejean A et al (2019) Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): update on carmena trial with focus on intermediate IMDC-risk population. J Clin Oncol 37(15 suppl):4508. https://doi.org/10.1200/JCO.2019.37.15_suppl.4508

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytoreductive nephrectomy in metastatic renal cell carcinoma;Cochrane Database of Systematic Reviews;2024-06-07

2. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis;JNCI: Journal of the National Cancer Institute;2024-03-14

3. The impact of primary region resection on the therapeutic outcome of combination regimens for metastatic renal cell carcinoma;Oncology Letters;2023-09-20

4. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis;Urologic Oncology: Seminars and Original Investigations;2023-03

5. The role of cytoreductive nephrectomy in the immuno-oncological therapy era;Current Opinion in Urology;2023-01-09